Mien-Chie Hung

Mien-Chie Hung

Auto-generated profile, based on publicly available information

Mien-Chie Hung

The University of Texas MD Anderson Cancer Center, Houston, TX

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2002
Verified
Journal Article
Closed access
FMFunda Meric
Funda Meric
WLWei-Ping Lee
Wei-Ping Lee
ASAysegul Sahin
Aysegul Sahin
HZHaixia Zhang
Haixia Zhang
HKHsing-Jien Kung
Hsing-Jien Kung
MHMien-Chie Hung
Mien-Chie Hung

1 March 2004 in Cancer Research
Verified
Journal Article
Open access
PDF file
CLChristine M. Lee
Christine M. Lee
HLHui-Wen Lo
Hui-Wen Lo
RSRu-Ping Shao
Ru-Ping Shao
SWShao-Chun Wang
Shao-Chun Wang
WXWeiya Xia
Weiya Xia
MHMien-Chie Hung
Mien-Chie Hung
Gene therapy provides a novel treatment approach to cancer patients. Ideally, expression of therapeutic genes driven by cancer-specific promoters would only target tumors resulting in minimal toxicity to normal tissues. While there is a need of more effective and tolerable treatments for ovarian cancer patients, we aimed to identify gene promoters with high activity in ovarian tumors that can be potentially used in gene therapy to drive the expression of a therapeutic gene in tumors. To identify such promoters, a literature search was performed to reveal genes that are preferentially expressed in ovarian cancer compared with normal ovarian tissue. We found that the ceruloplasmin promoter drove up to 30-fold higher luciferase expression in ovarian cancer cells compared with immortalized normal cells. Furthermore, deletion studies revealed an activator protein-1 (AP-1) site in the ceruloplasmin promoter to be critical for optimal ceruloplasmin promoter activity. Ceruloplasmin promoter activity was significantly activated by 1-O-tetradecanoyl phorbol-13-acetate, a c-jun activator, and conversely suppressed by SP600125, a c-jun inhibitor. Consistently, the ceruloplasmin AP-1 site was specifically recognized by c-jun both in vitro and in vivo. Immunohistochemical analyses of human ovarian cancer specimens showed a direct correlation (r = 0.7, P = 0.007) between expression levels of c-jun and ceruloplasmin. In nude mice carrying SKOV3.ip1 xenografts, the ceruloplasmin promoter demonstrated significantly higher activities in tumors compared with normal organs. Together, these results suggest that the ceruloplasmin promoter activity is significantly enhanced in ovarian cancer and therefore may be exploited as a promising cancer-specific promoter in developing new gene therapy strategies for ovarian cancer.

1 December 2003
Verified
Journal Article
Closed access
AHAshraful Hoque
Ashraful Hoque
JCJennifer Carter
Jennifer Carter
WXWeiya Xia
Weiya Xia
MHMien-Chie Hung
Mien-Chie Hung
ASAysegul A Sahin
Aysegul A Sahin
SLScott M Lippman
Scott M Lippman

1 January 2002
Verified
Journal Article
Closed access
YZYiyu Zou
Yiyu Zou
HPHua Peng
Hua Peng
BZBinhua Zhou
Binhua Zhou
YWYong Wen
Yong Wen
SWShao-Chun Wang
Shao-Chun Wang
MHMien-Chie Hung
Mien-Chie Hung

1 March 2002
Verified
Journal Article
Closed access
SWShao-Chun Wang
Shao-Chun Wang
RSRuping Shao
Ruping Shao
APAnnie Y Pao
Annie Y Pao
SZSu Zhang
Su Zhang
MHMien-Chie Hung
Mien-Chie Hung
LSLi-Kuo Su
Li-Kuo Su

15 October 2002
Verified
Journal Article
Closed access
SLSangkyou Lee
Sangkyou Lee
WYWentao Yang
Wentao Yang
KLKeng-Hsueh Lan
Keng-Hsueh Lan
SSShankar Sellappan
Shankar Sellappan
KKKristine Klos
Kristine Klos
DYDihua Yu
Dihua Yu